Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis. - Wikidata - awgldk - TriplyDB

Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis.

Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis.

http://www.wikidata.org/entity/Q37373820

about

When tuberculosis comes back: who develops recurrent tuberculosis in california?Isoniazid Mono-Resistant Tuberculosis: Impact on Treatment Outcome and Survival of Pulmonary Tuberculosis Patients in Southern Mexico 1995-2010 Use of a molecular diagnostic test in AFB smear positive tuberculosis suspects greatly reduces time to detection of multidrug resistant tuberculosis Cost Resulting from Anti-Tuberculosis Drug Shortages in the United States: A Hypothetical Cohort Study Rapid Molecular Detection of Multidrug-Resistant Tuberculosis by PCR-Nucleic Acid Lateral Flow Immunoassay Evolution of Extensively Drug-Resistant Tuberculosis over Four Decades: Whole Genome Sequencing and Dating Analysis of Mycobacterium tuberculosis Isolates from KwaZulu-Natal Prevalence, Risk Factors, and Treatment Outcomes of Isoniazid- and Rifampicin-Mono-Resistant Pulmonary Tuberculosis in Lima, Peru Diagnostic Molecular Mycobacteriology in Regions With Low Tuberculosis Endemicity: Combining Real-time PCR Assays for Detection of Multiple Mycobacterial Pathogens With Line Probe Assays for Identification of Resistance Mutations Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into the emergence and spread of multidrug resistance.Isoniazid-resistant tuberculosis: a cause for concern?Impact of isoniazid resistance-conferring mutations on the clinical presentation of isoniazid monoresistant tuberculosis Impact of a low-oxygen environment on the efficacy of antimicrobials against intracellular Chlamydia trachomatis.Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection.Isoniazid-resistant tuberculous meningitis, United States, 1993-2005.A prospective study of tuberculosis drug susceptibility in sabah, malaysia, and an algorithm for management of isoniazid resistance.A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs.Treatment outcomes of isoniazid-resistant tuberculosis patients, Western Cape Province, South Africa.First insights into circulating Mycobacterium tuberculosis complex lineages and drug resistance in Guinea.Treatment Outcomes with Fluoroquinolone-Containing Regimens for Isoniazid-Resistant Pulmonary Tuberculosis Ultra-short-course chemotherapy for spinal tuberculosis: five years of observation.Effect of mycobacterial drug resistance patterns on patients' survival: a cohort study in Thailand.Redefining MTBDRplus test results: what do indeterminate results actually mean?Outcomes among tuberculosis patients with isoniazid resistance in Georgia, 2007-2009 First Evaluation of GenoType MTBDRplus 2.0 Performed Directly on Respiratory Specimens in Central America Clinical characteristics and treatment outcomes of patients with low- and high-concentration isoniazid-monoresistant tuberculosis.Epidemiology of Drug-resistant Tuberculosis in a Tertiary Care Center in Oman, 2006-2015.Evaluation of two line probe assays for rapid detection of Mycobacterium tuberculosis, tuberculosis (TB) drug resistance, and non-TB Mycobacteria in HIV-infected individuals with suspected TB.Rapid detection of isoniazid resistance in Mycobacterium tuberculosis isolates by use of real-time-PCR-based melting curve analysis.Novel diagnostics and therapeutics for drug-resistant tuberculosis.Isoniazid-resistant tuberculosis in Birmingham, United Kingdom, 1999-2010.New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability.Isoniazid-monoresistant tuberculosis is associated with poor treatment outcomes in Durban, South Africa.The disconnect between a national tuberculosis drug resistance survey and treatment outcomes: a lost opportunity.Treatment outcomes for isoniazid-resistant tuberculosis under program conditions in British Columbia, Canada.Do we need to detect isoniazid resistance in addition to rifampicin resistance in diagnostic tests for tuberculosis?Time to Sputum Culture Conversion and Treatment Outcomes Among Patients with Isoniazid-Resistant Tuberculosis in Atlanta, Georgia.Need to confirm isoniazid susceptibility in Xpert MTB/RIF rifampin susceptible cases.Treatment duration for patients with drug-resistant tuberculosis, United States.Comparison of isoniazid monoresistant tuberculosis with drug-susceptible tuberculosis and multidrug-resistant tuberculosis.Isoniazid-Monoresistance and Rate of Culture Conversion among Confirmed Tuberculosis Patients in the State of Georgia, 2009 - 2014.

P2860

Q28393254-1697BC7B-8495-454D-861E-DEBEC5FE31FB Q28468519-B0455734-0D6D-497E-B59D-9A9789361457 Q28480576-A92ABAC5-E059-4614-98DE-C8DD2EB1FE87 Q28547335-963758B5-D122-4ED8-9DD4-505F607A61D1 Q28547835-1035D876-CA85-4015-82BD-701F50704FC9 Q28548604-57D3F185-43EF-467F-AE61-0709CA55F78F Q28551162-2E200F62-EEB1-4B48-9B32-8770962D6F43 Q28831411-6980DA65-8C19-48B4-A9B4-56EFDE98E820 Q33595994-412EE105-AD33-46C2-A820-C29BE2129E61 Q33820505-AF570D41-6506-4C9A-9CF6-9049B26283BA Q34287653-638BD801-AA8A-4CBB-B028-02A91EE2B59C Q34932613-EE6C6EFD-3A9D-4558-BB64-FAC66F68B85D Q35006626-22687042-7EF4-40D7-BAFD-1E49491C6F6E Q35193575-53921787-CC24-4ED3-8D7F-528937170704 Q35206899-B1F10784-308D-408F-B766-566DCF4C7638 Q35242238-E98072FB-8620-4ABD-BEE5-85067CD1B4DF Q35452446-E76A9783-FFBD-4620-AB7D-54D61FFD641C Q35856542-34ED685C-6220-4F3B-8C9A-7DE933BC2E9E Q36439006-3412AAE8-E297-40DC-8FCF-4FDBA684F0D0 Q36564239-E154D6EF-E642-4AB0-9EE4-7A56864D91F7 Q36647836-4ACD907F-C573-4843-AE75-A8A71079C68D Q36921992-EBD01888-0683-4B91-8ED2-C79BD071A04C Q37206044-25C440A2-7FF0-4BF6-8560-836C055F5796 Q37280660-5B4C5668-7482-4E8D-A826-A4D46B444233 Q37505650-B436E34A-9848-4D4E-8DA8-AF94E121AF69 Q37533167-9D4EFB0D-2922-44D7-8AC9-1ADF237E9954 Q37713474-369E5352-9DCF-420B-BDFA-7ADF8E8EE26D Q37713663-792EFD88-997A-4DE8-91C4-69A0956070FE Q38210363-60B6DAB2-8A35-4FB1-A71F-E9CF200FB50A Q38225730-6CAA14DC-A881-4D6A-8B90-2DCB7600E8E2 Q39895097-0E1FAF23-862C-499F-BD44-8A532524F68B Q40210228-0AE005D1-8B68-44FA-94FD-0B579BA1E072 Q40794783-64CF67E4-C237-40F3-8849-C68F58D6861C Q41611075-E78AAD31-7189-4F98-A776-5FBB9DB89E5E Q41849725-3FED6CAF-8DD7-42D7-80AB-84049AC9FF53 Q41987253-C13DC41D-610B-41A7-B6AE-462F3151F288 Q42742061-FA539B0D-B2E2-4443-B01E-741B5C838E58 Q43199807-89359FEA-7679-424E-BEF3-D62F72CFB758 Q43544463-540CE813-F4E8-46E1-9894-A341B95E2281 Q50048481-417BF5E9-1A4B-4FEA-AF6D-F6EB6E27E74F

P2860

Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis.

http://www.wikidata.org/entity/Q37373820

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Clinical characteristics and t ...... id-monoresistant tuberculosis.

@en

Clinical characteristics and t ...... id-monoresistant tuberculosis.

@nl

type

label

Clinical characteristics and t ...... id-monoresistant tuberculosis.

@en

Clinical characteristics and t ...... id-monoresistant tuberculosis.

@nl

prefLabel

Clinical characteristics and t ...... id-monoresistant tuberculosis.

@en

Clinical characteristics and t ...... id-monoresistant tuberculosis.

@nl

P1433

Q37373820-3F16C6B6-8AEF-4FCE-9722-0ACDFCBBA13A

P1476

Q37373820-51240C71-5836-407D-B3EC-1C998013F99A

P2093

Q37373820-264E620C-85B0-4899-85D1-DCE1D00976F8

Q37373820-547E0CD2-9DB0-4242-8AFA-757221326D17

Q37373820-81FA1248-6C42-4E95-A076-5C8FB74E1FFA

Q37373820-8842688C-34CF-43C4-A1E0-8FB1C4C0AD1C

Q37373820-B947181A-4DB6-4FA7-866C-5516D8BD8EDF

Q37373820-CA8ACAA8-2826-4C5E-AEB8-578BE051415F

Q37373820-D3F983E7-E55D-4A0D-AE29-6F307FB2FA6A

Q37373820-FD7BFF24-A486-4E43-A2AC-50A1F82F01C4

P2860

Q37373820-13DAEC89-A157-4204-9638-2604CC77C1F4

Q37373820-273E1AAE-647D-47A3-8EF1-659D97B45BC9

Q37373820-2B441D3B-67F1-46C1-8D11-519D9D9D5A92

Q37373820-4699D40C-460A-4A30-9BDF-C7E5B0A9E5B6

Q37373820-4736B9C2-F00F-4459-9C9B-CEFCB87134FE

Q37373820-5987A284-18EA-4592-8A46-E17D134D27F2

Q37373820-59C03235-6FEC-454C-9850-65F5811A3F51

Q37373820-662D187A-2A7D-42AC-A3A9-9B05E1698187

Q37373820-8BD7EA0D-FBAB-4A4B-82AE-9219278A39D0

Q37373820-8E4A8307-7F96-40F0-9B20-B6BA1EA9F92C

P304

Q37373820-ED26EC54-2101-4DC9-94C8-6DDB51FEF74D

P31

Q37373820-54CD61A9-E4A2-4AC6-8493-B54190F13A71

P356

Q37373820-12593E6D-EE9F-43F4-8699-A54CB07C64E7

P407

Q37373820-B666695D-2599-4A90-8049-0806C01F243B

P433

Q37373820-F1CA3C45-6F95-4417-BAD3-DBDDC04FA183

P478

Q37373820-AE7CD196-3F0E-4188-806F-F1F6E89493B3

P50

Q37373820-E339B129-C754-4675-94D3-A2E04447FCDD

P577

Q37373820-0150CA56-74EB-47C1-9635-8118FCC246CB

P5875

Q37373820-58506167-27B6-4961-8701-61AA66F0CF34

P698

Q37373820-A34118E5-6B71-4354-9941-5DF6A8A983CC

P921

Q37373820-E4B6141E-9739-4466-862D-D6BB68C05FDA

Q37373820-F3C79E6E-ADE4-4A7C-AB16-4F2226CC0498

P932

Q37373820-F0D4FA61-49CE-4104-8907-64B220FA1551

P356

P1433

Clinical Infectious Diseases

P1476

Clinical characteristics and t ...... zid-monoresistant tuberculosis

@en

P2093

Adithya Cattamanchi

http://www.w3.org/2001/XMLSchema#string

Dennis Osmond

http://www.w3.org/2001/XMLSchema#string

Jennifer Grinsdale

http://www.w3.org/2001/XMLSchema#string

John Z Metcalfe

http://www.w3.org/2001/XMLSchema#string

L Masae Kawamura

http://www.w3.org/2001/XMLSchema#string

Leah G Jarlsberg

http://www.w3.org/2001/XMLSchema#string

Philip C Hopewell

http://www.w3.org/2001/XMLSchema#string

Raymund B Dantes

http://www.w3.org/2001/XMLSchema#string

P2860

Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis

Molecular epidemiology of tuberculosis in the Netherlands: a nationwide study from 1993 through 1997.

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

Determinants of drug-resistant tuberculosis: analysis of 11 countries.

The genetics and biochemistry of isoniazid resistance in mycobacterium tuberculosis.

Effect of katG mutations on the virulence of Mycobacterium tuberculosis and the implication for transmission in humans.

Isoniazid preventive therapy and risk for resistant tuberculosis.

Isoniazid- and rifampin-resistant tuberculosis in San Diego County, California, United States, 1993-2002.

Isoniazid resistance and the future of drug-resistant tuberculosis.

Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis.

P304

179-185

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/595689

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

48

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23667902

http://www.w3.org/2001/XMLSchema#string

P698

19086909

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde

P932

2756509

http://www.w3.org/2001/XMLSchema#string